What's there not to like here:- Forecast increase in earnings by...

What's there not to like here:
- Forecast increase in earnings by 25%
- Annuity style sustainable and predictable license revenue
- Fixed cost base, with massive scale opportunity
- Nice % reinvestment of earnings into R&D each year
- Management own over 50% of the share base.
- Enough accumulated losses to not have to pay tax for a long time, I wonder if there is an opportunity for some tax rebates?
- No debt
- Nice EBITDA to cash conversion
- Sizzling sector, in fact exposure to 2 hot sectors, health and cloud based offerings
- Sweet spot market cap and revenue numbers
- Forward PE less than 10

The negatives:
- GLH was effectively recapitalised at 4.5c by the directors in 2012, it looks like the directors were the only ones that took up the rights. However for most of 2011 and 2012 this thing traded less than 10c, so it looks like there may be some stale bulls, locking in at these levels. I am happy to keep buying this thing, and welcome some sub 40c action.